CRPS Treatment: pain in hand and wrist for 5 months

Home / CRPS Case Studies Report

CRPS Treatment: pain in hand and wrist for 5 months

Contents

General details and patient's info

Gender:Female.
Age:59 years old at the time of treatment.
Home Country:United States of America.
Illness duration:5 months prior to the Neridronate Treatment.
Cause:Fracture of the elbow.
Symptoms:Squeezing pain in wrist and palm, stiff fingers, swelling. Unable to make a fist. Pain range is 6.
Clinical evaluation:CRPS diagnosis, with radial nerve damage. Unable to fully extend the left hand. Mild generalized soft tissues edema of the elbow.
Time of treatment:March 2019.

Why the Patient decided to undergo the CRPS Treatment in Italy

The patient was referred to a Pain Center in the USA, but she did not feel comfortable and well followed there. She started searching online, discovered Neridronate option and understood the importance of receiving it at soonest.

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)
See the Official Study on the Oxford Academics website: https://academic.oup.com/rheumatology/article/52/3/534/1777330
4 Pantoprazole infusions; Paracetamol.

2 sessions, 2 hours each, of Neuromuscular Rehabilitation Treatment with the Osteopath and Physiotherapist.
Rehabilitation therapy is a full body workout which focuses on the general wellbeing of the body, to help the affected limb get back to its normal self.

Daily Report

DAY 1: Arrival at the Venice airport, greeted by her Patient Manager, followed by check-in at her Hotel in Vicenza. Briefing focused on next days.

DAY 2: Morning pick-up by her Patient Manager, 1st visit with the Rheumatologist Professor, 1st Neridronate infusion.

DAY 3: Morning pick-up by her Patient Manager, 2nd Neridronate infusion, then touring of Verona.

DAY 4: Morning pick-up by her Patient Manager, 1st rehabilitation session.

DAY 5: Morning pick-up by her Patient Manager, 3rd Neridronate infusion and 2nd visit with the Rheumatologist Professor. Visit of Soave city.

DAY 6: Morning pick-up by her Patient Manager and 2nd rehabilitation session.

DAY 7: Morning pick-up by her Patient Manager, last Neridronate infusion. The patient never reported side effects, today she even feels less pain in her hand.

DAY 8: Morning meeting with Patient Manager and rest day.

DAY 9: Morning pick-up by her Patient Manager and day trip to Venice.

DAY 10: Morning pick-up by her Patient Manager and drop-off at Venice airport.

Follow up

AUGUST 2019 (5 months after Neridronate treatment): the patient feels better, her hand is less swollen and red. She keeps on following the physiotherapy program suggested in Italy.

OCTOBER 2019 (7 months after Neridronate treatment): the patient feels better, pain decreased, she can now use her hands more freely.

Conclusion

Even though it was not stated by the patient’s Neurologist Doctor, it seems likely that this could have been a case of CRPS type 2, which involves nerve damage.
Neridronate has been effective on this woman, and she has been able to go back to her activities. The pain decreased, she can now use her hands more freely.
Return to Case Study reports
Contact us for the evaluation of your case

DISCLAIMER
This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.